Preferential Selectivity of Inhibitors with Human Tau Protein Kinase Gsk3𝜷 Elucidates Their Potential Roles for Off-Target Alzheimer’s Therapy

Table 1

Details of 10 tau kinases used in the analysis.

Sl. number	Protein name	UniProt ID	PDB ID	Number of residues	Ligand present in the PDB structure	Nomenclature of inhibitors in the study
(1)	Glycogen synthase kinase 3 beta (GSK3β)	P49841	1J1C	420	Adenosine-5′-diphosphate	—
(2)	Cyclin-dependent kinase 5 (CDK5)	Q00535	3O0G	292	4-Amino-2-[[4-chlorophenyl]amino]-1,3-thiazol-5-yl][3-nitrophenyl]methanone	Inhibitor 1
(3)	p38 delta kinase (p38)	O15264	3COI	365	No Ligand	—
(4)	Mitogen-activated protein kinase 1 (Erk1/2)	P28482	1TVO	360	5-[2-Phenylpyrazolo[1,5-a]pyridin-3-yl]-1h-pyrazolo[3,4-c]pyridazin-3-amine [Drug Bank ID DB07794]	Inhibitor 2
(5)	Mitogen-activated protein kinase 10 (JNK3)	P53779	2O0U	464	N-{3-Cyano-6-[3-[1-piperidinyl]propanoyl]-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl}1-naphthalenecarboxamide	Inhibitor 3
(6)	Casein kinase 1 delta (CK1d)	P48730	3UYT	415	4-[1-Cyclohexyl-4-[4-fluorophenyl]-1H-imidazol-5-yl]pyrimidin-2-amine	Inhibitor 4
(7)	Dual-specificity tyrosine-[Y]-phosphorylation-regulated kinase 1A (DYRK1A)	Q13627	3ANR	763	7-Methoxy-1-methyl-9h-beta-carboline [harmine complex] [Drug Bank ID DB07919]	Inhibitor 5
(8)	Protein kinase A (PKA)	P17612	3MVJ	351	[3R]-1-[5-Methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrolidin-3-amine	Inhibitor-6 (3-aminopyrrolidine scaffold)
(9)	Protein kinase B (PKB/AKT)	P31749	3MV5	480	[3R]-1-[5-Methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]pyrrolidin-3-amine	Inhibitor-6 (3-aminopyrrolidine scaffold)
(10)	Protein kinase C alpha (PKC)	P17252	3IW4	672	3-[1H-Indol-3-yl]-4-[2-[4-methylpiperazin-1-yl]quinazolin-4-yl]-1H-pyrrole-2,5-dione	Inhibitor 7